300244 迪安诊断
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,246,960-5.00%10,096,03212,196,22413,408,32020,282,469
减:营业总成本2,058,244-8.40%9,550,98111,403,54612,243,28216,603,821
    其中:营业成本1,584,708-8.97%7,222,1468,779,6079,213,38312,745,811
               财务费用33,805-21.00%156,601198,032220,608298,236
               资产减值损失(1,052)-25.58%(96,289)(401,579)(16,738)(624,025)
公允价值变动收益2,107-17.85%3,528(12,697)(727)(56,236)
投资收益(11,473)75.63%26,19438,713(17,596)48,787
    其中:对联营企业和合营企业的投资收益(11,421)174.05%18,04011,584(6,722)26,763
营业利润156,728569.11%281,315(31,115)842,1832,822,609
利润总额154,682646.77%256,190(51,826)798,3262,543,562
减:所得税费用50,466205.09%110,584117,407216,735681,092
净利润104,2162,397.82%145,606(169,233)581,5911,862,470
减:非控股权益39,84258.24%101,554188,045274,130428,279
股东净利润64,374-406.46%44,053(357,278)307,4611,434,191

市场价值指针
每股收益 (元) *0.105-406.10%0.072-0.5790.4922.302
每股派息 (元) *----0.3500.9000.0600.200
每股净资产 (元) *10.443-0.26%10.30810.50312.06911.881
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容